Results 151 to 160 of about 413,185 (307)

Scalable Engineering of Bio‐Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient‐Derived Models

Advanced Science, EarlyView.
Engineered extracellular vesicles displaying Ephrin‐B2 selectively target Ephrin‐B4–expressing ovarian cancer cells, enabling precise delivery in patient‐derived models. This scalable bio‐manufacturing platform reveals a versatile strategy to exploit Ephrin signaling for highly specific therapeutic payload delivery and motivates exploration of tailored
Nihar Godbole, Andrew Lai, Alexander Quinn, Marianne Gillard, Dominic Guanzon, Katherin Scholz‐Romero, Alexis Salas‐Burgos, Bastián Lillo Dapremont, Rohan Lourie, Naven Chetty, Richard Lobb, Kate Beecher, Amy E. McCart Reed, Kaltin Ferguson, Biao Sun, Yaowu He, John D. Hooper, Carlos Salomon   +17 more
wiley   +1 more source

Light‐Switched Mesenchymal Stem Cells for In Situ Exosome Amplification in Craniofacial Bone Defect Reconstruction

Advanced Science, EarlyView.
Light‐switchable MSCs (MSC‐UCNPs) were constructed by intracellular incorporation of UCNPs. Upon 980 nm irradiation, UCNPs emitted localized ultraviolet light (365 nm), activating the ROS/HEXB/LAMP1 signaling pathway to suppress lysosome–multivesicular body fusion and thereby enhance exosome biogenesis. Embedded within an injectable hydrogel, MSC‐UCNPs
Tingting Wu, Yajing Liu, Shuman Wang, Xiaoming Bai, Luyun Zhang, Yuwei Liu, Zhiwen Fu, Chen Shi   +7 more
wiley   +1 more source

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

Annals of Gastroenterological Surgery, EarlyView.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata, Tetsuya Tajima, Satoshi Ogiso, Shinji Uemoto, Etsuro Hatano   +4 more
wiley   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

Two Surgical Cases of Thymic Tumor Requiring Resection and Reconstruction of the Superior Vena Cava and the Brachiocephalic Vein. [PDF]

Ann Vasc Dis
Shirakawa M, Kimura H, Amitani R, Suzuki K, Miyagi Y, Honda J, Suzuki K, Sonokawa T, Machida Y, Kawasaki N, Usuda J, Ishii Y.   +11 more
europepmc   +1 more source

Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

American Journal of Hematology, EarlyView.
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen, Joachim Baech, Mikkel Porsborg Andersen, Harman Yonis, Paw Jensen, Peter Kamper, Jacob H. Christensen, Rasmus Bo‐Dahl Sørensen, Martin Hutchings, Christian Torp‐Pedersen, Peter Sogaard, Henrik Boggild, Kristian H. Kragholm, Tarec C. El‐Galaly   +13 more
wiley   +1 more source

Multiday Use of Non-Tunneled Central Venous Catheters in Vetted Adult Outpatients Undergoing Apheresis Collections of Autologous Peripheral Blood Stem Cells Is Feasible and Well Tolerated. [PDF]

J Clin Apher
Mindiola Romero AE, Griggs JR, Rollins-Raval MA, Fero ML, Raval JS.   +4 more
europepmc   +1 more source

Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

American Journal of Hematology, EarlyView.
ABSTRACT In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...
Gaspar Aspas Requena, Rebeca Rodríguez‐Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa del Bernal del Castillo, Eva Barragan, Mar Tormo, Eduardo Rodríguez Arbolí, Josefina Serrano López, Raimundo García Boyero, Tamara Castaño, Pilar Herrera Puente, Mónica A. Romero Riquelme, María J. Sayas Lloris, Lorenzo Algarra‐Algarra, Carlos Rodriguez‐Medina, Claudia L. Sossa Melo, Jorge Labrador Gomez, Susana Vives, Olga Salamero, María Luz Amigo, Marta Valero Nuñez, Christine Rojas, Francisca Bass, María García‐Fortes, Belén Vidriales Vicente, Marta Polo, Celina Benavente, María D. Madrigal, Marcela Espinoza, Manuel Pérez‐Encinas, María L. Amador Barciela, Guiomar Bautista, Antonio Solana‐Altabella, Isabel Cano‐Ferri, Rafael Colmenares, Patricia García‐Ramírez, Francisco Ibáñez Alis, Manuel Barrios García, Gabriela Rodríguez‐Macías, Miguel López, Ana Yurena Oliva Hernández, Carlos Javier Cerveró, David Martínez‐Cuadrón, Pedro Chorão, Juan M. Bergua Burgues, Pau Montesinos   +49 more
wiley   +1 more source

Oral health-related quality of life and dental treatment need 5 to 10 years after hematopoietic cell transplantation. [PDF]

Support Care Cancer
van Leeuwen SJM, van Gennip LLA, van Swam L, van de Ven MWJ, Blijlevens NMA, Huysmans MDNJM.   +5 more
europepmc   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, EarlyView.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source